Definitive Contract 75N91021C00023
Award Date
9/16/21
Potential Completion Date
6/15/22
Potential Value
$396K
Federal Agency
National Cancer Institute
Awardee
Earlydiagnostics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Los Angeles, CA 90095, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,994,911.00 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract was awarded under the NCI SBIR Transition to Phase II Solicitation for fiscal year 2023 and has a total small business set-aside designation. Earlydx, a for-profit organization, will provide research and development services to support the development of a cloud-based...
<p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Health Agency (DHA) to Emergingdx Inc., a small business based in Mansfield, Massachusetts. The contract, valued at $1,299,988.98, supports the development of an automated detection platform for circulating and exosomal microRNAs. This research and development effort is focused on medical diagnostics and aligns with the DHA's mission to advance healthcare technologies. The contract was awarded on...
This federal contract award is for a Small Business Innovation Research (SBIR) Phase I project from the Defense Health Agency (DHA) to Emergingdx Inc., a small business subchapter S corporation based in Mansfield, Massachusetts. The contract, valued at $249,993.61, supports the development of a "Rapid, Automated, Multiplexed Omics Platform" for medical research and diagnostic applications. As a total small business set-aside contract, this award demonstrates Emergingdx Inc.'s expertise...
<p>This is a small business set-aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients undergoing radiation therapy, as part of the Small Business Innovation Research (SBIR) program. The definitive, firm-fixed price contract has a ceiling value of $280,005.00 and a performance period ending on March 31, 2015.</p>
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Diagnologix, LLC, a self-certified small disadvantaged business, for the development of "SBIR 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER." The firm-fixed-price contract, with a potential value of $350,000.00, has a completion date of August 31, 2018. This SBIR...
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
The Department of Health and Human Services National Institutes of Health National Cancer Institute (NIH NCI) awarded a Small Business Innovation Research (SBIR) Phase II contract to L2 Diagnostics LLC, a for-profit limited liability company, to develop predictive biomarkers for adverse reactions to prostate cancer radiotherapy. The $1,996,011.00 firm-fixed-price contract has a completion date of September 18, 2020 and is set aside for small businesses. L2 Diagnostics is a provider of goods...
This is a firm fixed price SBIR Phase I contract awarded by the Department of the Navy Secretary of the Navy Office of Naval Research to Emergingdx Inc., a for-profit subchapter S corporation. The $239,636.00 contract funds research under the SBIR Program to advance disease detection and precision medicine capabilities. Emergingdx Inc. has also received several other recent SBIR and STTR Phase I awards from the Defense Health Agency and Department of Agriculture to develop biosensors, microRNA...
This definitive firm fixed price contract was awarded by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, to Digital Nanogenetics LLC on September 17, 2018. With a potential value of $300,000, the contract is associated with the Small Business Innovation Research Program Phase I and has a completion date of September 19, 2019. The contract has a set aside designation for total small businesses and will support research...